129 related articles for article (PubMed ID: 24182219)
61. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
[TBL] [Abstract][Full Text] [Related]
62. Screening for prostate cancer remains controversial.
Neal DE; Donovan JL; Martin RM; Hamdy FC
Lancet; 2009 Oct; 374(9700):1482-3. PubMed ID: 19664817
[No Abstract] [Full Text] [Related]
63. New tests promise smarter prostate cancer screening and treatment. Clues from genes and other cancer markers can help men make decisions, but come with important limitations.
Harv Mens Health Watch; 2013 Dec; 18(5):6-7. PubMed ID: 27024839
[No Abstract] [Full Text] [Related]
64. States renewing attention to prostate cancer.
Rossiter C
NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
[No Abstract] [Full Text] [Related]
65. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
66. Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others.
Printz C
Cancer; 2018 Jan; 124(1):11-12. PubMed ID: 29251768
[No Abstract] [Full Text] [Related]
67. Screening for prostate cancer. The U.S. Preventive Services Task Force.
Am Fam Physician; 1990 Oct; 42(4):991-4. PubMed ID: 2220525
[No Abstract] [Full Text] [Related]
68. The feasibility of multiparametric magnetic resonance imaging for targeted biopsy using novel navigation systems to detect early stage prostate cancer: the preliminary experience.
Mouraviev V; Verma S; Kalyanaraman B; Zhai QJ; Gaitonde K; Pugnale M; Donovan JF
J Endourol; 2013 Jul; 27(7):820-5. PubMed ID: 22966987
[TBL] [Abstract][Full Text] [Related]
69. Prostate-specific antigen testing and prostate cancer screening.
Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
[TBL] [Abstract][Full Text] [Related]
70. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
71. Screening for prostate cancer: an updated review.
Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
[TBL] [Abstract][Full Text] [Related]
72. Refining the assessment of the sensitivity and specificity of diagnostic tests, with applications to prostate cancer screening and non-small cell lung cancer staging.
Berger VW; Semanick L
Rev Panam Salud Publica; 2005 Jul; 18(1):64-70. PubMed ID: 16105328
[No Abstract] [Full Text] [Related]
73. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
74. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
75. Active surveillance criteria for prostate cancer: can they be applied to Japanese patients?
Goto Y; Nozumi K; Miyazaki K; Matsumoto A; Inoue A; Kito H; Hasegawa N; Nagata M; Kakuta Y; Suzuki H; Yamaguchi K
Int J Urol; 2012 Feb; 19(2):163-6. PubMed ID: 22070372
[TBL] [Abstract][Full Text] [Related]
76. Towards an optimal interval for prostate cancer screening.
van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
[TBL] [Abstract][Full Text] [Related]
77. Using real-world evidence to support a changing paradigm for cancer screening: A commentary.
Leavy MB; Starzyk K; Myers E; Curhan G; Gliklich R
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1312-1315. PubMed ID: 32902061
[No Abstract] [Full Text] [Related]
78. Prostate cancer screening.
Ackermann RJ
CA Cancer J Clin; 1990; 40(3):190-2. PubMed ID: 2110026
[No Abstract] [Full Text] [Related]
79. Solid Science for the Upside but Lack of Solid Science for the Downside-Towards Cutting-edge Prostate-cancer Screening.
Steineck G; Akre O; Bill-Axelson A
Eur Urol; 2019 Jul; 76(1):52-53. PubMed ID: 30975451
[No Abstract] [Full Text] [Related]
80. Evidence-based truths about the benefit of cancer screening.
Wilkinson AN
Can Fam Physician; 2024 May; 70(5):296. PubMed ID: 38744517
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
